Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
Baxter International Inc. announced that its European subsidiary has received a contract from the National Health Service (NHS) in the United Kingdom to produce a stockpile of two million doses of candidate H5N1 influenza vaccine based on an avian strain. Under the agreement, Baxter will complete delivery of the stockpile to the NHS in 2006.
Baxter also is working with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a cell culture-based H5N1 candidate pandemic influenza vaccine. Baxter will be providing the candidate vaccine to NIAID for clinical testing in the United States, which is expected to be initiated in 2006. In addition, Baxter is in discussions with several other governments regarding its candidate pandemic vaccine.
Cell-based systems for production of vaccines offer a number of potential benefits over more traditional, chicken egg-based systems. Baxter's vero-cell system is capable of producing high yields of influenza virus without the addition of any animal-derived serum. Through the company's research and development work, Baxter has been successful in growing wild-type virus in its vero-cell culture, which means that the company could begin vaccine production without having to wait for high-growth or attenuated virus reassortants normally used when vaccine is produced in eggs.
Most read news
Organizations
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Air Products' Nitrogen Recovery Unit Equipment Selected for ExxonMobil Texas Project
Former Royal Society of Chemistry Chief Executive Dr Richard Pike dies

Copper(I) interlocks rings and rods
NREL bolsters batteries with nanotubes
125 years of Rhein Chemie: Committed to innovation and sustainability for over a century
ABB wins $80 million order from Samsung Heavy Industries
Successful Field-Trial Remediation of 1,2-DCA and VC Contaminated Groundwater in Northern Italy
CEM Corporation increases revenues
Boehringer Ingelheim microParts to expand production capacity in Dortmund
By-product of Teflon manufacture used to generate compounds for medicinal, agrichemical and materials sciences
The european commission imposes a fine on certain monochloroacetic acid producers
